Flag of the European Union EU Clinical Trials Register Help

Clinical trials for double placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9,473 result(s) found for: double placebo. Displaying page 1 of 474.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000678-44 Sponsor Protocol Number: GA1116 Start Date*: 2012-09-04
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single-centre, randomised, four-way crossover study to investigate the measurement of the acid pocket and subsequent gastro-oesophageal reflux episodes using a novel pH/impedance catheter in subj...
    Medical condition: A single-centre, randomised, four-way crossover study to investigate the measurement of the acid pocket and subsequent gastro-oesophageal reflux episodes using a novel pH/impedance catheter in subj...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004725-27 Sponsor Protocol Number: GA1109 Start Date*: 2012-01-24
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single-centre, randomised, double-blind, two-way crossover, placebo-controlled pilot study, investigating the use of a novel intragastric and oesophageal pH catheter to characterise the antacid a...
    Medical condition: To pilot the use of a novel pH catheter for the measurement of oesophageal and intragastric pH comparing the onset and duration of antacid action of Gaviscon Double Action versus placebo.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002188-84 Sponsor Protocol Number: GA1203 Start Date*: 2012-07-27
    Sponsor Name:Reckitt Benckiser Healthcare (UK) LTD
    Full Title: A multi-centred, randomised, double-blind, two arm, parallel group, placebo-controlled, pilot study to assess the effect of Gaviscon Double Action Tablets in patients with reflux disease
    Medical condition: This pilot study of Gaviscon Double Action Tablets is to be conducted to demonstrate that Gaviscon Double Action Tablets are effective in managing the symptoms of heartburn, acid regurgitation and ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003737-29 Sponsor Protocol Number: BUU-5/EEA Start Date*: Information not available in EudraCT
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, Phase II/III trial on the efficacy and tolerability of treatment with budesonide oral suspension vs. placebo in children and adolescents with eosinophi...
    Medical condition: Active eosinophilic esophagitis and maintenance of remission in eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PT (Completed) NL (Completed) GR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-021630-63 Sponsor Protocol Number: GA1001 Start Date*: 2011-03-28
    Sponsor Name:Reckitt Benckiser
    Full Title: A randomised, double blind placebo controlled study in patients with reflux symptoms to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Peppermint liquid’ using the BRAVO...
    Medical condition: Gastro-oesophageal reflux disease (GORD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004131-23 Sponsor Protocol Number: GA1212 Start Date*: 2013-01-18
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single-centre, randomised, 2 way crossover, double blind, placebo controlled study in healthy volunteers, to characterise the antacid activity of Gaviscon Double Action Mint Liquid in the fasted ...
    Medical condition: This study is to demonstrate the antacid action of Gaviscon Double Action Mint versus a matched placebo using a pH catheter.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001389-39 Sponsor Protocol Number: VLX-601 Start Date*: 2022-04-19
    Sponsor Name:Mirum Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (VANTAGE)
    Medical condition: Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10019805 - Hepatobiliary disorders 10080429 Primary biliary cholangitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001717-17 Sponsor Protocol Number: P1901GF Start Date*: 2019-10-23
    Sponsor Name:Pohl-Boskamp GmbH & Co. KG
    Full Title: A multi-centre, randomised, placebo-controlled, double-blind parallel-group trial to assess the efficacy and safety of SIA capsules in subjects with acute rhinosinusitis.
    Medical condition: acute rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10040754 Sinusitis acute NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001178-31 Sponsor Protocol Number: YO42137 Start Date*: 2020-08-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WH...
    Medical condition: Esophageal squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10055476 Esophageal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) HU (Completed) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014388-38 Sponsor Protocol Number: NEUAZ1 Start Date*: 2009-09-28
    Sponsor Name:Neurim Pharmaceuticals Ltd
    Full Title: A double-blind, parallel group, randomized, placebo controlled study of the efficacy of Circadin® 2mg in alleviating sleep disturbances in patients with mild to moderate Alzheimer Disease (AD) tre...
    Medical condition: Insomnia in patients with mild to moderate Alzheimers Disease.
    Disease: Version SOC Term Classification Code Term Level
    10. 10036701 Primary Insomnia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002794-35 Sponsor Protocol Number: CPDR001F2301 Start Date*: 2017-02-20
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated pati...
    Medical condition: Unresectable or metastatic BRAF V600 mutant melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) AT (Completed) CZ (Completed) PL (Completed) BG (Completed) GR (Completed) BE (Completed) PT (Completed) NL (Completed) DK (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000765-78 Sponsor Protocol Number: ROSE-01 Start Date*: 2017-07-18
    Sponsor Name:Medis, d.o.o.
    Full Title: Randomized, Double-blind, Placebo Controlled Clinical Study To Evaluate Analgesic Efficacy of Topically Administered Traditional Herbal Medicinal Product for Relief of Acute Muscular Pain.
    Medical condition: Acute Muscular Pain
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001382-32 Sponsor Protocol Number: BCT-521-201 Start Date*: 2019-11-26
    Sponsor Name:Beckley Canopy Therapeutics Ltd.
    Full Title: A Double-Blind, Randomized Phase 1/2 Study to Assess the Efficacy and Safety of BCT-521 Versus Placebo for Pain Associated With Cancer in Patients Already Receiving Standard of Care Treatment With ...
    Medical condition: Pain associated with cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000103-20 Sponsor Protocol Number: 202000638 Start Date*: 2021-07-15
    Sponsor Name:University Medical Center Groningen
    Full Title: An explorative randomized, placebo-controlled and double-blind intervention crossover study: Transvamix (100mg/mL THC / 50mg/mL CBD) to treat chronic pain in Epidermolysis Bullosa
    Medical condition: Genetic Epidermolysis Bullosa
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002211-18 Sponsor Protocol Number: CAMG334A2301 Start Date*: 2016-10-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140 mg AMG 334 against placebo in adult episodic migraine patients who have fail...
    Medical condition: Migraine Prevention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) SE (Completed) DE (Completed) FI (Completed) ES (Completed) AT (Completed) DK (Completed) BE (Completed) GR (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000539-42 Sponsor Protocol Number: RB2-NL-1518 Start Date*: 2016-04-15
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A randomised, single dose, crossover, open label, placebo controlled confirmatory study in healthy volunteers to characterise the acid neutralisation activity of Gaviscon Double Action Liquid in th...
    Medical condition: To investigate the pH of the acid in the stomach of healthy volunteers after the intakeof Gaviscon Double Action liquid.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000804-24 Sponsor Protocol Number: D1690C00024 Start Date*: 2015-07-06
    Sponsor Name: AstraZeneca AB
    Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III study to Evaluate the Glycemic Efficacy and Renal Safety of dapagliflozin in patients with Type 2 Diabetes Mel...
    Medical condition: Type 2 Diabetes Mellitus with Moderate Renal Impairment (CKD 3A)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) ES (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023992-24 Sponsor Protocol Number: MEMAP1 Start Date*: 2011-08-26
    Sponsor Name:University of Leipzig
    Full Title: International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate
    Medical condition: acute mania and hypomania (ICD-10: F30.0, F30.1, F31.0, F31.1)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10000852 Acute mania LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-003034-27 Sponsor Protocol Number: BN29552 Start Date*: 2016-07-13
    Sponsor Name:Roche Farma, S.A en nombre de F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODOMAL-TO-MILD ALZHEIMER?S DISEASE
    Medical condition: Alzheimer?s Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) HU (Completed) PT (Prematurely Ended) CZ (Completed) FI (Prematurely Ended) BE (Prematurely Ended) DK (Completed) AT (Prematurely Ended) SI (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) BG (Completed) HR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001883-21 Sponsor Protocol Number: I5Q-MC-CGAI Start Date*: 2016-01-18
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Study
    Medical condition: Chronic Migraine Headache
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 13:06:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA